A Phase 3b Open-label Study Evaluating the Effects of Elexacaftor/Tezacaftor/Ivacaftor on Cough and Physical Activity in Cystic Fibrosis Subjects 12 Years of Age and Older Who Are Heterozygous for the F508del Mutation and a Minimal Function Mutation

Project Details

Effective start/end date5/07/2131/07/23


  • Vertex Pharmaceuticals (Aust) Pty Ltd: A$105,000.00
  • Vertex Pharmaceuticals (Aust) Pty Ltd: A$30,503.00